This reference uses the specific documents linked in the article and listed below. Check their scope, publication dates and the statements they support.
What fails in the skin?
The UC Davis Center for Equine Health explains that abnormal collagen affects the skin's structural integrity. Stretching, tearing and scarring can occur, particularly along the back. The disorder may be present before obvious wounds develop, so the first visible lesion is not necessarily the beginning of the underlying condition.
This helps explain why a horse can have an inherited problem despite appearing normal as a newborn. It also means that a wound appearing under a saddle should be assessed on its merits. Its location raises a question; it does not establish whether the cause is HERDA, another skin disorder or a local injury.
An examination should not create another wound
The clinical concern is the horse's actual skin and comfort. Describe lesions, when they appeared and the handling or equipment in use at the time. Do not pull or stretch the skin to demonstrate its fragility for a video. A veterinarian can decide how to examine the animal without an owner repeatedly reproducing the injury.
If work or equipment seems to be aggravating a lesion, contact the treating team about the immediate plan. Replacing one pad with another cannot establish the diagnosis or show that the skin is safe under further pressure. Avoid treating a genetic suspicion as a reason to postpone attention to painful or open lesions.
Affected, carrier and clear are different results
The UC Davis Veterinary Genetics Laboratory describes HERDA as autosomal recessive. In its notation, N/HRD denotes a carrier and HRD/HRD denotes an affected genotype. A carrier is not expected to develop HERDA from the tested variant, but can pass it to offspring. An N/N result means that the tested variant was not detected.
| Result in the laboratory's notation | What it means for this variant |
|---|---|
| N/N | No copies detected |
| N/HRD | One copy; carrier |
| HRD/HRD | Two copies; affected genotype |
Read the result with the laboratory's own explanation and the horse's identity. The word “positive” alone is too vague for a breeding or clinical discussion. A carrier result does not explain every wound on that horse, while an affected result needs to be connected to an appropriate veterinary welfare plan.
Why appearance cannot identify every carrier
A horse that looks healthy can still be a carrier. This is a consequence of the recessive inheritance pattern, rather than evidence that the test conflicts with the examination. The genetic result and the clinical findings describe different features of the animal.
Conversely, a lesion that resembles a published photograph does not identify the genotype. Give the veterinarian any existing report instead of relying on remembered panel shorthand. If the report belongs to a parent, label it as the parent's result; do not substitute it for an individual result from the horse being assessed.
Understanding the one-in-four breeding risk
The laboratory explains that two carriers have a 25% probability of producing an affected foal. This is a probability for each pregnancy under the stated parental genotypes. It does not mean that four foals must include exactly one affected foal, or that three apparently healthy foals guarantee the fourth will be affected.
A breeding discussion should therefore begin with supported results for both proposed parents. Pedigree information can help frame the question, but a prominent ancestor's name does not replace those results. Ask the laboratory or veterinarian to explain any unfamiliar notation and the scope of the test before making a pairing decision.
No curative treatment changes the planning question
The Center for Equine Health describes no cure for HERDA and explains that affected horses can have major welfare limitations. Some require intensive management even outside riding work. A plan should consider the individual horse's comfort and the likelihood of repeated injury, rather than judging success only by whether one wound closes.
Discuss prognosis and humane options with the veterinarian. A quiet period is useful information, but it cannot demonstrate that the underlying skin structure has become normal. Likewise, an animal's potential use should not be decided from an internet photograph or a generic description of another affected horse.
What a practical care discussion should cover
Ask how routine handling, the living environment and any necessary veterinary care can be managed for this horse. The team needs to understand what contact and equipment the horse normally encounters. An abstract instruction to “avoid trauma” is less useful than a plan that caretakers can apply to the horse's daily circumstances.
Agree how comfort and new injuries will be reviewed. If several people share care, identify the person responsible for reporting a change and contacting the veterinarian. That continuity matters when a chronic inherited condition creates recurring problems rather than one isolated accident.
A fictional example: a panel result described as positive
Imagine an owner who receives an N/HRD result and tells the yard that the horse “has HERDA.” The wording can cause unnecessary confusion. The report identifies a carrier of the tested variant, not the affected two-copy genotype. The carrier's unrelated skin wound still needs its own assessment.
Now imagine a different horse with an HRD/HRD report and repeated back lesions. That combination leads to a different clinical and welfare discussion. Keeping the complete result with the correct animal prevents two distinct situations from being collapsed into the same label.
Related inherited conditions need their own interpretation
The horse hub connects the wider equine reference library. HYPP has a different inheritance pattern and clinical mechanism; the meaning of one detected copy cannot be transferred between the two conditions. GBED is another distinct recessive disorder with very different effects on affected foals.
The clinical and laboratory UC Davis references used here come from the same institution. They provide complementary explanations of disease and testing; they should not be counted as two independent outcome studies.
Common questions
Does normal skin exclude carrier status?
No. A carrier can be clinically unaffected while retaining reproductive significance for the tested variant.
Is every wound under tack evidence of HERDA?
No. Its location is an observation for assessment. The examination, relevant history and appropriate genetic interpretation must be considered together.
Does a carrier result certify every other aspect of health?
No. A result concerns the specified variant. It does not replace examination or testing for unrelated clinical questions.
Cite this reference
LivestockDefense. “HERDA in horses: fragile skin, genetic results and welfare.” Updated 2026-10-31. https://livestockdefense.com/threats/equine-hereditary-equine-regional-dermal-asthenia/
Add the date you accessed the page. This identifies the current reference; keep a permitted saved copy if your work depends on its exact wording. A citation alone does not establish support for a claim.
How to cite a page and its revision ↗Sources & boundaries
Read the evidence in context.
These documents support the statements identified in this reference. Check their scope and dates when deciding whether they answer your question.
- UC Davis Veterinary Genetics Laboratory: Hereditary Equine Regional Dermal Asthenia (HERDA)
Source update: Not provided. Most recent check: 2026-10-31.
Explains recessive HERDA inheritance, the laboratory’s N/N, N/HRD and HRD/HRD results and the probability of an affected foal from two carriers. A result concerns the tested variant and must remain attached to the correct horse.
- UC Davis Center for Equine Health: Hereditary Equine Regional Dermal Asthenia (HERDA)
Source update: 2019-07-05. Most recent check: 2026-10-31.
Describes abnormal skin structure, lesions and scarring, recognition around the start of riding work and serious welfare limitations. It is a clinical explanation from the same institution as the laboratory reference, not an independent treatment trial.
